/MEDXF

MEDXF Stock - Medexus Pharmaceuticals Inc.

Q: What is the analyst price target for MEDXF?

Analyst price target information is not currently available for MEDXF.

Q: What is MEDXF's market cap?

Market capitalization information is not currently available for MEDXF.

Healthcare|Drug Manufacturers - Specialty & Generic|OTC

$1.93-0.41%

$0.01 (-0.41%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $2.12

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for MEDXF

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2021

FY2022

FY2023

FY2024

FY2025

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.90

52W High$3.88

52W Low$1.43

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$108.33M	$113.05M	$108.10M	$76.70M	$79.66M
Gross Profit	$56.58M	$59.51M	$60.04M	$37.93M	$42.01M
Gross Margin	52.2%	52.6%	55.5%	49.4%	52.7%
Operating Income	$8.22M	$10.79M	$7.61M	$-14,996,000	$-1,376,000
Net Income	$2.25M	$-214,000	$1.22M	$-2,879,000	$-28,264,000
Net Margin	2.1%	-0.2%	1.1%	-3.8%	-35.5%
EPS	$0.08	$-0.01	$0.06	$-0.15	$-1.86

Company Overview

Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. It focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, and allergy. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, a prescription allergy medication. Its products portfolio also includes Treosulfan, a bifunctional alkylating agent for allogeneic hematopoietic stem cell transplantation; Trispan, a triamcinolone hexacetonide injectable suspension; and Gleolan, an optical imaging agent indicates for patients with glioma symptoms. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Bolton, Canada.

Visit Website

Earnings History & Surprises

MEDXF

Beat Rate

73%

Last 15 quarters

Avg Surprise

-264.9%

EPS vs Estimate

Beats / Misses

11/4

Last 12 quarters

Latest EPS

$-0.01

Q4 2025

EPS Surprise History

Q1 24

-158.7%

$-0.02vs$-0.01

Q2 24

No data

Q3 24

+100.0%

$0.08vs$0.04

Q4 24

+99.4%

$0.00vs$0.00

Q1 25

+50.0%

$0.03vs$0.02

Q1 25

No data

Q2 25

+57.1%

$-0.03vs$-0.07

Q4 25

+80.5%

$-0.01vs$-0.05

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q1 2026	Feb 11, 2026	—	—	—	—
Q4 2025	Nov 12, 2025	$-0.05	$-0.01	+80.5%	✓ BEAT
Q2 2025	Jun 25, 2025	$-0.07	$-0.03	+57.1%	✓ BEAT
Q1 2025	Mar 31, 2025	—	$-0.01	—	—
Q1 2025	Feb 5, 2025	$0.02	$0.03	+50.0%	✓ BEAT
Q4 2024	Nov 7, 2024	$0.00	$0.00	+99.4%	✓ BEAT
Q3 2024	Aug 7, 2024	$0.04	$0.08	+100.0%	✓ BEAT
Q2 2024	Apr 17, 2024	—	$0.02	—	—
Q1 2024	Feb 8, 2024	$-0.01	$-0.02	-158.7%	✗ MISS
Q4 2023	Nov 8, 2023	$-0.01	$-0.05	-327.4%	✗ MISS
Q3 2023	Aug 9, 2023	$0.01	$0.03	+349.8%	✓ BEAT
Q1 2023	Mar 31, 2023	—	$0.23	—	—
Q1 2023	Feb 8, 2023	$-0.08	$-0.07	+12.5%	✓ BEAT
Q4 2022	Nov 8, 2022	$-0.21	$-0.14	+33.3%	✓ BEAT
Q3 2022	Aug 8, 2022	$-0.20	$-0.18	+10.0%	✓ BEAT
Q1 2022	Mar 31, 2022	—	$-0.21	—	—
Q1 2022	Feb 9, 2022	$-0.39	$-0.17	+56.4%	✓ BEAT
Q4 2021	Nov 10, 2021	$-0.53	$-0.32	+39.6%	✓ BEAT
Q3 2021	Aug 16, 2021	$-0.02	$-0.28	-1286.1%	✗ MISS
Q1 2021	Mar 1, 2021	$-0.03	$-0.93	-3090.4%	✗ MISS

Frequently Asked Questions about MEDXF

What is MEDXF's current stock price?

Medexus Pharmaceuticals Inc. (MEDXF) is currently trading at $1.93 per share. The stock has moved -0.41% today.

What is the analyst price target for MEDXF?

No analyst price targets are currently available for this stock.

What sector is Medexus Pharmaceuticals Inc. in?

Medexus Pharmaceuticals Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the OTC exchange.

What is MEDXF's market cap?

Medexus Pharmaceuticals Inc. has a market capitalization of $0.06 billion, making it a small-cap company.

Does MEDXF pay dividends?

No, Medexus Pharmaceuticals Inc. does not currently pay a dividend to shareholders.